Table 1 Relationship between miR-5195-3p expression and clinicopathological characteristics of patients with prostate cancer
From: MiR-5195-3p functions as a tumor suppressor in prostate cancer via targeting CCNL1
Characteristic | Case (n = 69) | miR-5195-3p expression | p-Value | |
|---|---|---|---|---|
Low (n = 35) | High (n = 34) | (chi-squared test) | ||
Age (year) | 0.733 | |||
< 65 | 21 | 10 | 11 | |
≥ 65 | 48 | 25 | 23 | |
Preoperative PSA (ng/ml) | 0.368 | |||
< 10 | 43 | 20 | 23 | |
≥ 10 | 26 | 15 | 11 | |
Gleason score | 0.001* | |||
< 7 | 51 | 20 | 31 | |
≥ 7 | 18 | 15 | 3 | |
TNM stage | 0.006* | |||
I/II | 46 | 18 | 28 | |
III/IV | 23 | 17 | 6 | |
Metastasis | 0.118 | |||
No | 39 | 23 | 16 | |
Yes | 30 | 12 | 18 | |